A Game-Changer in Antimicrobial Resistance
Battle
ZÜRICH, April 29, 2024
/PRNewswire/ -- In a significant stride towards preventing
antimicrobial resistance, Smart Blood Analytics Swiss proudly
announces the attainment of EU-MDR (European Medical Device
Regulation)1 certification for their VIRUS vs. BACTERIA
Clinical Decision Support Software. This innovative medical device
sets a new benchmark in accurately distinguishing between viral and
bacterial infections, thus aiding physicians in delivering targeted
and effective treatment to patients.
Antimicrobial resistance (AMR) poses a significant threat to
global public health and development, contributing to millions of
deaths annually. Mainly driven by the misuse and overuse of
antibiotics, AMR undermines the effectiveness of treatments for
infectious diseases, putting modern medical advancements at risk
and increasing healthcare costs substantially. The World Health
Organization (WHO) emphasizes preventing infections, ensuring
universal access to quality diagnosis and treatment, and promoting
innovation in surveillance and research to address antimicrobial
resistance in human health.2
As the first Clinical Decision Support Software to receive
EU-MDR certification in the field of infectious disease management,
VIRUS vs. BACTERIA utilizes only 17 routine blood parameters,
biological sex, and age to distinguish between viral and bacterial
infections. The VIRUS vs. BACTERIA model has also recently been
showcased in an article published in Heliyon, highlighting its
effectiveness and great accuracy
(https://doi.org/10.1016/j.heliyon.2024.e29372).
With routine blood testing being readily available worldwide,
VIRUS vs. BACTERIA greatly expands the doctor's capacity to
differentiate between viral and bacterial infections and aids in
the rational use of antibiotics, especially in the range where
other commonly used blood markers offer limited diagnostic
value.
The idea to develop VIRUS vs. BACTERIA was inspired by the 2022
G20 Bali summit, where a Call to
Action on antimicrobial resistance was presented3. It
emphasized the urgent need for innovative solutions to combat the
growing worldwide threat of AMR, often referred to as the silent
pandemic. This event convened global leaders to address the
challenges, and it highlighted the importance of collaborative
efforts to develop effective strategies for infection
management.
Dr. Marko Notar, CEO of Smart
Blood Analytics Swiss, shared his excitement about the EU-MDR
certification, stating, "This achievement shows our commitment to
advancing healthcare through innovation. By providing clinicians
with a precise tool to differentiate between viral and bacterial
infections, we aim to empower doctors with more information and
help them in their decision of antibiotic prescriptions. This
contributes to more effective healthcare practices."
The EU-MDR certification process involves a thorough and
extensive evaluation of medical device safety, quality, and
compliance with European Union regulations governing medical
devices. Smart Blood Analytics Swiss is committed to maintaining
the highest standards of safety, performance, and
compliance, and this EU-MDR certification reaffirms its
ongoing dedication to excellence in the healthcare industry.
In an era where healthcare challenges demand innovative
solutions, VIRUS vs. BACTERIA emerges as a solution of great
promise. Being available to use worldwide and with its
user-friendly interface and powerful capabilities, this
cutting-edge tool stands ready to empower healthcare professionals
in their battle against antimicrobial resistance.
For media inquiries, please contact:
Manca Köster
manca@sba-swiss.com
+41 78 244 01 26
About Smart Blood Analytics Swiss:
Smart Blood Analytics Swiss is a forward-thinking healthcare
technology company dedicated to transforming the medical diagnostic
process. Their EU-MDR-certified flagship product, SBAS Software,
employs artificial intelligence to enhance the accuracy and
efficiency of the interpretation of blood test results. With a
commitment to excellence and a focus on patient well-being, Smart
Blood Analytics Swiss is at the forefront of innovation in
healthcare, continuously developing new products in the field of
blood test result interpretation. This includes pioneering
solutions that provide a deeper dive into understanding and
recommending which blood parameters contribute to the decisions
that determine the right diagnosis for the patient.
For more information on how Smart Blood Analytics Swiss can help
transform the medical diagnostic process, visit:
www.smartbloodanalytics.com.
1 Regulation (EU) 2017/745 on Medical Devices
2
https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
3 https://www.g20.org/en
Logo -
https://mma.prnewswire.com/media/2398607/Smart_Blood_Analytics_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/smart-blood-analytics-swiss-achieves-eu-mdr-certification-for-virus-vs-bacteria-model-302128710.html